# A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women

> **NCT00952887** · PHASE1 · COMPLETED · sponsor: **Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA** · enrollment: 70 (actual)

## Conditions studied

- Muscular Atrophy

## Interventions

- **BIOLOGICAL:** ACE-031
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00952887
- **Lead sponsor:** Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2011-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00952887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00952887, "A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00952887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*